Focusing Capital on Key Therapeutic Areas

Belgian UCB is refining its growth strategy by expanding its clinical and commercial capabilities in immunology and neurology. Its key revenue driver, Bimzelx (bimekizumab-bkzx), a single-clone antibody targeting IL-17A and IL-17F, generated €2.227 billion in net sales in 2025, and UCB projects peak sales exceeding €4 billion. The FDA approved Bimzelx for moderate-to-severe plaque psoriasis on October 17, 2023, without convening an advisory committee. The acquisition of next-generation platforms, based on a proven commercial foundation, forms the financial basis of this strategy.

Acquisition of Candel Therapeutics Secures an Immunology Reset Platform

UCB completed the acquisition of Candel Therapeutics on June 17, 2026, with an upfront payment of USD $2.0 billion and potential milestones totaling USD $0.2 billion, for a total of up to USD $2.2 billion. Its key asset, cizutamig, is a clinical-stage, brand-agnostic BCMA·CD3 bispecific T-cell engager designed to eliminate pathogenic plasma cells and B cells, and is being evaluated in multiple Phase 1 clinical trials for more than 10 autoimmune indications. Based on initial datasets from over 100 patients, global Phase 2 clinical trials for myasthenia gravis and systemic autoimmune disease-associated interstitial lung disease will drive development. The ability to achieve deeper and more sustained immune reset compared to existing treatments such as Rituxan (rituximab, CD20), Vyvgart (efgartigimod alfa, FcRn), and Ultomiris (ravulizumab, C5) will be a key competitive differentiator.

Diversifying Risk with CD19 and Neurological Cell Therapy

UCB also secured global exclusive development, manufacturing, and commercialization rights for ATG-201 from Antengene (6996). ATG-201 is a CD19·CD3 bispecific antibody, with Antengene conducting the first-in-human Phase 1 clinical trial in China and Australia, followed by UCB taking over subsequent development. In neurology, UCB completed the acquisition of Neurona Therapeutics on June 2, 2026, for an upfront payment of USD $0.65 billion and milestones totaling USD $0.50 billion, for a total of up to USD $1.15 billion, securing rezanecel (formerly NRTX-1001). Rezanecel is a single-dose regenerative neural cell therapy for drug-resistant medial temporal lobe epilepsy, currently in Phase 1/2 clinical trials, and represents a disease-modifying approach that complements standard treatment with anti-epileptic drugs and epilepsy surgery.

Revenue Defense and Clinical Execution Will Determine Valuation

The autoimmune therapeutics market was USD $144.1 billion in 2025, and the global epilepsy drug market was USD $11.1 billion in 2024, indicating significant commercial expansion potential for both platforms. UCB's Rystiggo (rozanolixizumab-noli), an FcRn-targeted antibody, is a marketed product approved by the FDA on June 26, 2023, for adult patients with acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibody-positive generalized myasthenia gravis, and can share development costs for new programs. However, cizutamig and rezanecel are in Phase 1 and Phase 1/2 clinical stages, respectively, making efficacy replication, cytokine release syndrome management, and cell manufacturing consistency key risk factors. Therefore, the success of these acquisitions will depend more on the speed of Phase 2 transition and the demonstration of risk-benefit profiles for each indication than on platform scarcity.